KONINKLIJKE NEDERLANDSE CENTRALE VERENIGING TOT BESTRIJDING DER TUBERCULOSE (KNCV)

Their core work

KNCV (Royal Netherlands Tuberculosis Association) is a Dutch public health NGO with over a century of expertise in tuberculosis prevention, control, and elimination. Their real-world work spans community-based case-finding programs in high-burden countries (Vietnam, Nepal), clinical trial design and execution, and applied research bridging field epidemiology with laboratory science. In EU research, they contribute field implementation capacity and programmatic TB expertise that academic partners cannot replicate — they know how TB control actually works on the ground in low- and middle-income countries. In their most recent project, they bring this operational knowledge into an industry-academic collaboration focused on new TB drug regimens and AI-enabled clinical trial platforms.

What they specialise in

How they've shifted over time

In their earlier H2020 work (2017–2019), KNCV focused on field-level public health intervention — specifically community-based active case detection in endemic countries, with no apparent focus on laboratory science or drug development. By their second project (2021–2028), their profile shifted decisively toward clinical and translational research: new chemical entities, drug regimens, clinical pharmacology, and AI-enabled trial platforms. The trend reflects a broadening of KNCV's role from purely programmatic implementer to clinical research partner capable of bridging field TB control with drug development pipelines.

KNCV is moving toward clinical and translational research partnerships, making them a valuable bridge between TB drug developers and real-world implementation capacity in high-burden settings.

How they like to work

KNCV has participated in all H2020 projects as a consortium member rather than coordinator, suggesting they prefer to contribute specialised TB expertise without taking on the administrative lead role. Both their projects are large, multi-partner RIA consortia — UNITE4TB in particular spans a wide academia-industry network. This pattern indicates they are sought-after specialist contributors rather than project drivers, brought in for their unique operational and clinical TB capabilities.

KNCV has built a network of 37 unique consortium partners across 14 countries through just 2 projects, indicating involvement in broad international consortia. Their partnerships span European academic institutions, industry players, and likely high-burden country partners given their field work in Vietnam and Nepal.

What sets them apart

KNCV is one of the few European NGOs combining a century of TB-specific operational experience with active participation in cutting-edge clinical trial and drug development research. Unlike academic TB groups, they bring real-world program delivery experience in endemic settings — a capability that is rare and difficult to substitute in consortia targeting low- and middle-income countries. For any consortium working on TB diagnostics, treatment, or elimination, KNCV provides credibility, field access, and implementation know-how that academic or industry partners typically lack.

Highlights from their portfolio

• UNITE4TB
  Largest project by budget (€1.57M to KNCV) and longest duration (2021–2028), uniting academia and pharma industry for new TB drug development with AI-assisted trial platforms — a landmark TB R&D initiative.
• IMPACT TB
  Demonstrates KNCV's unique field implementation capacity through active TB case-finding programs deployed in Vietnam and Nepal, outside the EU research mainstream.